Treatment of POEMS syndrome with bevacizumab

Haematologica

Volumn 92, Issue 10, 2007, Pages 1438-1439

  Samaras, Panagiotis ^a   Bauer, Stefan ^a   Stenner Liewen, Frank ^a   Steiner, Rudolf ^a   Zweifel, Martin ^a   Renner, Christoph ^a   Knuth, Alexander ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Bevacizumab; Plasma cell; POEMS; Pulmonary hypertension; VEGF

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ILOPROST; IMMUNOGLOBULIN; MELPHALAN; PREDNISONE; SILDENAFIL; STEROID; VASCULOTROPIN;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER MORTALITY; CASE REPORT; DATA ANALYSIS; DIARRHEA; DRUG MECHANISM; DRUG MEGADOSE; GENERALIZED EDEMA; HUMAN; MALE; MOTOR NEUROPATHY; MULTIPLE ORGAN FAILURE; PARAPROTEINEMIA; PULMONARY HYPERTENSION; SENSORY NEUROPATHY; SWELLING;

ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; POEMS SYNDROME;

EID: 36348937889     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11315     Document Type: Article

References (7)

1. Watanabe O, Maruyama I, Arimura K, Kitajima I, Arimura H, Hanatani M, et al. Overproduction of vascular endothelial growth factor/vascular permeability factor is causative in Crow-Fukase (POEMS) syndrome. Muscle Nerve 1998; 21: 1390-7.
2. Badros A, Porter N, Zimrin A. Bevacizumab therapy for POEMS syndrome. Blood 2005;106:1135.
3. Straume O, Bergheim J, Ernst P. Bevacizumab therapy for POEMS syndrome. Blood 2006;107:4972-3.
4. Dispenzieri A. POEMS Syndrome. Am Soc Hematol Educ Program 2005:360-7.
5. Podar K, Anderson KC. The pathophysiologic role of VEGF in hematologic malignancies: therapeutical implications. Blood 2005;105:1383-95.
6. Hitoshi S, Suzuki K, Sakuta M. Elevated serum interleukin-6 in POEMS syndrome reflects the activity of the disease. Intern Med 1994;33:583-7.
7. Voelkel NF, Cool C, Taraceviene-Stewart L, Geraci MW, Yeager M, Bull T, et al. Janus face of vascular endothelial growth factor: the obligatory survival factor for lung vascular endothelium controls precapillary artery remodeling in severe pulmonary hypertension. Crit Care Med 2002; 30 Suppl 5:S251-6.